GIGABYTE
14.4.2020 11:02:06 CEST | Business Wire | Press release
The leading personal computer brand, GIGABYTE, recently received the 2020 Red Dot Design Award for two creator laptops from the AERO line – AERO 15 OLED & AERO 17 – as well as two professional gaming laptops – AORUS 15G and AORUS 17X. The recognition further establishes GIGABYTE’s role as a market leader in the laptop industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200414005017/en/
There were over 6,500 entries from 60 countries contending in this year’s Red Dot Design Awards. GIGABYTE is committed to producing the AERO Creator Laptop and AORUS Gaming Laptop lines in Taiwan. With their ultra-slim bezel, Xrite Pantone color calibration, Microsoft Azure AI, and other industry leading technologies, GIGABYTE’s laptops have already been recognised with the European Hardware Awards for Best Notebook as well as receiving Taiwan Excellence Awards. The notebooks are now honored with the 2020 Red Dot Design Award.
AORUS: Redefining Gaming Laptops
AORUS laptops are fast and powerful, with screens that offer a high refresh rate coupled with exceptional mechanical keyboards. In 2020, AORUS takes it further by collaborating with G2 Esports, a professional global esports team, to develop a purpose-built gaming laptop that caters to professional gamer’s needs. The comprehensive and integrative design concept was crucial for GIGABYTE in winning the award.
The product design is infused with a sense of extreme performance, with the flagship AORUS 17X being inspired by super cars and a fighter jet. The chassis is created using CNC (Computer Numerical Control) technology, carving the all-aluminum chassis into a robust frame with defined angles. RGB LED lights are scattered from end to end showcasing the flagship laptop’s overwhelming speed and power.
The second winning laptop, the brand new AORUS 15G, is a professional gaming laptop for on-the-road gamers: though also equipped with a mechanical keyboard, the AORUS 15G is lighter and has a longer lasting battery. The design of AORUS 15G was also inspired by sports cars with the side of the chassis embellished with faux race car features to create a feel of extreme sports while adding a touch of minimalist modernism.
AERO: An Equilibrium of Performance and Mobility
The aesthetic of the creator laptops in the AERO line are inspired by science fiction films. The full aluminum chassis is finished with NIL (Nano-Imprint Lithography), presenting superior quality that is simple but by no means underwhelming. Steven Chen, VP of GIGABYTE’s Mobile Business Center, stated that the beauty of AERO laptops lies in “more possibilities” and therefore they must have lighter bodies, long-lasting batteries, and great performance without any compromise due to overheating.
The AERO line is well-balanced in many aspects, visual artist Rus Khasonov was inspired by AERO to create videos with the AERO 15 OLED, “With AERO, I can render with After Effects and edit with Photoshop at the same time. I’m deeply impressed that such a light body can offer such performance.”
The full line of creator laptops from AERO, including the 15” AERO 15 OLED and 17” AERO 17 HDR with 4K monitors as well as the AERO 15 and AERO 17 with FHD monitors, are available starting on 16th April. The graphics card powerhouse, NVIDIA, is upping the prize for creators and has promised free access to Adobe Creative Cloud for three months to anyone buying the RTX Studio equipped models. For details, please refer to the official website: https://www.gigabyte.com/Laptop
- ENDS -
About GIGABYTE
GIGABYTE is an engineer, visionary, and leader in the world of tech that uses its hardware expertise, patented innovations, and industry leadership to create, inspire and advance. Renowned for over 30 years of award-winning excellence, GIGABYTE is a cornerstone in the HPC community, providing businesses with server and data center expertise to accelerate their success. At the forefront of evolving technology, GIGABYTE is devoted to inventing smart solutions that enable digitalization from edge to cloud, and allow customers to capture, analyze, and transform digital information into economic data that can benefit humanity and "Upgrade Your Life". Please visit https://www.gigabyte.com/ for more information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200414005017/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom